LABELS · 39c67c8f-7fbd-a17a-1535-5d41ece68818

Adalimumab

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-01-12
Captured: 2026-09-09T23:37:44.904352+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products including Adalimumab-fkjp are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue Adalimumab-fkjp if a patient develops a serious infection or sepsis. Reported infections include: • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before Adalimumab-fkjp use and during therapy. Initiate treatment for latent TB prior to Adalimumab-fkjp use. • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with Adalimumab-fkjp prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Adalimumab-fkjp, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions (5.2) ]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. SERIOUS INFECTIONS ( 5.1 , 6.1 ): • Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. • Discontinue adalimumab-fkjp if a patient develops a serious infection or sepsis during treatment. • Perform test for latent TB; if positive, start treatment for TB prior to starting Adalimumab-fkjp. • Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): • Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. • Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.

Indications and usage: exact source text

1 INDICATIONS AND USAGE Adalimumab-fkjp is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. J uvenile Idiopathic Arthritis (JIA) ( 1.2 ) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. A nkylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients. 1.1 Rheumatoid Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-fkjp can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-fkjp can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-fkjp can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-fkjp is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease Adalimumab-fkjp is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-fkjp is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7 ) ] . 1.7 Plaque Psoriasis Adalimumab-fkjp is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-fkjp should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa Adalimumab-fkjp is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis Adalimumab-fkjp is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.

Full extracted label fields

application numbers

BLA761154

boxed warning exact

WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products including Adalimumab-fkjp are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue Adalimumab-fkjp if a patient develops a serious infection or sepsis. Reported infections include: • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before Adalimumab-fkjp use and during therapy. Initiate treatment for latent TB prior to Adalimumab-fkjp use. • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with Adalimumab-fkjp prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Adalimumab-fkjp, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions (5.2) ]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. SERIOUS INFECTIONS ( 5.1 , 6.1 ): • Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. • Discontinue adalimumab-fkjp if a patient develops a serious infection or sepsis during treatment. • Perform test for latent TB; if positive, start treatment for TB prior to starting Adalimumab-fkjp. • Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): • Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. • Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.

brand names

Adalimumab

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cde907d-6747-0e62-db25-1718ee717fe7

generic names

ADALIMUMAB-FKJP

39c67c8f-7fbd-a17a-1535-5d41ece68818

indications and usage exact

1 INDICATIONS AND USAGE Adalimumab-fkjp is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. J uvenile Idiopathic Arthritis (JIA) ( 1.2 ) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. A nkylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients. 1.1 Rheumatoid Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-fkjp can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-fkjp can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-fkjp can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-fkjp is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease Adalimumab-fkjp is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-fkjp is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7 ) ] . 1.7 Plaque Psoriasis Adalimumab-fkjp is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-fkjp should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa Adalimumab-fkjp is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis Adalimumab-fkjp is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.

indications and usage tables exact

is original packager

true

manufacturer names

Biocon Biologics Inc

matched search terms

tumor

package ndcs

83257-020-42
83257-021-42
83257-022-32

product ndcs

83257-020
83257-021
83257-022

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

rxcuis

797544
2640404
2640412
2640417

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00200.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA761154

brand names

Adalimumab

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 531
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Adalimumab-fkjp is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. J uvenile Idiopathic Arthritis (JIA) ( 1.2 ) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. Psoriatic Arthritis (PsA) ( 1.3 ) :
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 0

current approval status

not_reconciled

duplicate text group

dup-b2fc71aff29483ceb115

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-c7167d86473d5f6b1404

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

end: 90
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 40

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with moderately to severely active RA.
kind
age
polarity
not_inferred
span
end
292
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
278

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 331
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Adalimumab-fkjp is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · unclassified context

application numbers

BLA761154

brand names

Adalimumab

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 695
end exclusive: true
exact text: educing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. J uvenile Idiopathic Arthritis (JIA) ( 1.2 ) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. A nkylosing Spondy
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 132

current approval status

not_reconciled

duplicate text group

dup-e4bcc7da18958b82e05d

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-826ec67fb488c17a7a86

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

Source null

qualifier mentions

context exact
moderately to severely active polyarticular JIA in patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
484
end exclusive
true
exact text
2 years of age
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
470

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 495
end exclusive: true
exact text: J uvenile Idiopathic Arthritis (JIA) ( 1.2 ) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 332

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · positive indication candidate

application numbers

BLA761154

brand names

Adalimumab

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 876
end exclusive: true
exact text: h moderately to severely active RA. J uvenile Idiopathic Arthritis (JIA) ( 1.2 ) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. A nkylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 296

current approval status

not_reconciled

duplicate text group

dup-e6ce0c6a952214ab4be0

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-2f7926b330a42815f8af

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

end: 90
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 40

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with active PsA.
kind
age
polarity
not_inferred
span
end
659
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
645

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 676
end exclusive: true
exact text: Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 496

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 4 · positive indication candidate

application numbers

BLA761154

brand names

Adalimumab

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 976
end exclusive: true
exact text: of age and older. Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. A nkylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. Ulcerative Colitis (UC) ( 1.6 ): treatment of moder
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 477

current approval status

not_reconciled

duplicate text group

dup-35903242afe05b722495

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-aaa0c714f0002d87abde

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

end: 90
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 40

qualifier mentions

context exact
ng Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS.
kind
age
polarity
not_inferred
span
end
760
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
746

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 776
end exclusive: true
exact text: A nkylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 677

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 5 · unclassified context

application numbers

BLA761154

brand names

Adalimumab

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1124
end exclusive: true
exact text: rogression of structural damage, and improving physical function in adult patients with active PsA. A nkylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 577

current approval status

not_reconciled

duplicate text group

dup-2ef03bddba4cd5166a7e

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-f7a2ad1d52b2956c5037

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

Source null

qualifier mentions

context exact
eatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
875
end exclusive
true
exact text
adults
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
869
context exact
moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
898
end exclusive
true
exact text
pediatric patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
880
context exact
ely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
913
end exclusive
true
exact text
6 years of age
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
899

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 924
end exclusive: true
exact text: Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 777

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

BLA761154

brand names

Adalimumab

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1238
end exclusive: true
exact text: igns and symptoms in adult patients with active AS. Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with m
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 725

current approval status

not_reconciled

duplicate text group

dup-0254d5f4d2f85a15e511

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-33734c39b03875e9c459

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

Source null

qualifier mentions

context exact
ment of moderately to severely active ulcerative colitis in adult patients.
kind
age
polarity
not_inferred
span
end
1037
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
1023

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1038
end exclusive: true
exact text: Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 925

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · limitation of use

application numbers

BLA761154

brand names

Adalimumab

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1372
end exclusive: true
exact text: ely active Crohn’s disease in adults and pediatric patients 6 years of age and older. Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 839

current approval status

not_reconciled

duplicate text group

dup-7edf25178a85d0ed09e1

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-a8b5541a49e2d58267de

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1172
end exclusive: true
exact text: Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 1039

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 8 · unclassified context

application numbers

BLA761154

brand names

Adalimumab

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1603
end exclusive: true
exact text: derately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuv
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 973

current approval status

not_reconciled

duplicate text group

dup-27b7330dec893254cda5

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-a5fb7c335974ea712aac

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

Source null

qualifier mentions

context exact
Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
kind
age
polarity
not_inferred
span
end
1231
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
1217

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1403
end exclusive: true
exact text: Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 1173

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

BLA761154

brand names

Adalimumab

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1718
end exclusive: true
exact text: treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients. 1.1 Rheumatoid Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms, ind
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 1204

current approval status

not_reconciled

duplicate text group

dup-363fba49847c939a98d7

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-2f1fe6fd1b15c6419faf

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

Source null

qualifier mentions

context exact
treatment of moderate to severe hidradenitis suppurativa in adult patients.
kind
age
polarity
not_inferred
span
end
1517
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
1503

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1518
end exclusive: true
exact text: Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 1404

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

BLA761154

brand names

Adalimumab

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1827
end exclusive: true
exact text: y or phototherapy, and when other systemic therapies are medically less appropriate. Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients. 1.1 Rheumatoid Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical functi
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 1319

current approval status

not_reconciled

duplicate text group

dup-963798b46db8f2b0b52a

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-55c191dab1a7605d305b

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

Source null

qualifier mentions

context exact
f non-infectious intermediate, posterior, and panuveitis in adult patients.
kind
age
polarity
not_inferred
span
end
1626
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
1612

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1627
end exclusive: true
exact text: Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 1519

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · positive indication candidate

application numbers

BLA761154

brand names

Adalimumab

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2104
end exclusive: true
exact text: (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients. 1.1 Rheumatoid Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-fkjp can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-fkjp is indic
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 1428

current approval status

not_reconciled

duplicate text group

dup-e7ada16253fd4724103c

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-5cab757e2e0018e2c7ce

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

end: 1681
end exclusive: true
exact text: is indicated
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 1669

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
kind
age
polarity
not_inferred
span
end
1847
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
1833

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1904
end exclusive: true
exact text: 1.1 Rheumatoid Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 1628

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 12 · unclassified context

application numbers

BLA761154

brand names

Adalimumab

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2245
end exclusive: true
exact text: symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-fkjp can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 1705

current approval status

not_reconciled

duplicate text group

dup-217a2788a824e2a104fd

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-83efdaf5902edbe3a21a

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

Source null

qualifier mentions

context exact
Adalimumab-fkjp can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
kind
biomarker
polarity
not_inferred
span
end
2005
end exclusive
true
exact text
methotrexate or other non-biologic disease-
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
1962
context exact
Adalimumab-fkjp can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
kind
regimen
polarity
not_inferred
span
end
2044
end exclusive
true
exact text
in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs)
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
1942

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 2045
end exclusive: true
exact text: Adalimumab-fkjp can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 1905

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · positive indication candidate

application numbers

BLA761154

brand names

Adalimumab

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2455
end exclusive: true
exact text: s with moderately to severely active rheumatoid arthritis. Adalimumab-fkjp can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-fkjp can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms, inhibiting the progression of structural d
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 1846

current approval status

not_reconciled

duplicate text group

dup-5ed28084819642ff9855

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-9b69aab03e2b9d29ec3f

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

end: 2108
end exclusive: true
exact text: is indicated
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2096

qualifier mentions

context exact
ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
2244
end exclusive
true
exact text
2 years of age
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
2230

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 2255
end exclusive: true
exact text: 1.2 Juvenile Idiopathic Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2046

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 14 · unclassified context

application numbers

BLA761154

brand names

Adalimumab

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2526
end exclusive: true
exact text: le Idiopathic Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-fkjp can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active ps
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2056

current approval status

not_reconciled

duplicate text group

dup-c9bec0857a16f99224c3

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-bef8c8992c21be2e8e72

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

Source null

qualifier mentions

context exact
Adalimumab-fkjp can be used alone or in combination with methotrexate.
kind
biomarker
polarity
not_inferred
span
end
2325
end exclusive
true
exact text
methotrexate
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
2313
context exact
Adalimumab-fkjp can be used alone or in combination with methotrexate.
kind
regimen
polarity
not_inferred
span
end
2325
end exclusive
true
exact text
in combination with methotrexate
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
2293

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 2326
end exclusive: true
exact text: Adalimumab-fkjp can be used alone or in combination with methotrexate.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2256

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 15 · positive indication candidate

application numbers

BLA761154

brand names

Adalimumab

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2744
end exclusive: true
exact text: and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-fkjp can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-fkjp can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-fkjp is indicated for reducing signs and symptoms in adult patients with active ank
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2127

current approval status

not_reconciled

duplicate text group

dup-5ad00bbd1fd58d648b8f

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-5f81fc0e3420bc1065a9

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

end: 2379
end exclusive: true
exact text: is indicated
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2367

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
kind
age
polarity
not_inferred
span
end
2511
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
2497

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 2544
end exclusive: true
exact text: 1.3 Psoriatic Arthritis Adalimumab-fkjp is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2327

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 16 · unclassified context

application numbers

BLA761154

brand names

Adalimumab

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2822
end exclusive: true
exact text: ritis Adalimumab-fkjp is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-fkjp can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-fkjp is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease Adalimumab-fkjp is indicated for the
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2345

current approval status

not_reconciled

duplicate text group

dup-59ca4583291d29b4d594

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-441a0270ba6b3c9a3f49

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

Source null

qualifier mentions

context exact
Adalimumab-fkjp can be used alone or in combination with non-biologic DMARDs.
kind
regimen
polarity
not_inferred
span
end
2621
end exclusive
true
exact text
in combination with non-biologic DMARDs
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
2582

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 2622
end exclusive: true
exact text: Adalimumab-fkjp can be used alone or in combination with non-biologic DMARDs.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2545

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 17 · positive indication candidate

application numbers

BLA761154

brand names

Adalimumab

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2964
end exclusive: true
exact text: the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-fkjp can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-fkjp is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease Adalimumab-fkjp is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis A
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2423

current approval status

not_reconciled

duplicate text group

dup-ea62fba3550e9892560a

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-e32cf333b9963c34f0f7

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

end: 2678
end exclusive: true
exact text: is indicated
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2666

qualifier mentions

context exact
imumab-fkjp is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
kind
age
polarity
not_inferred
span
end
2728
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
2714

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 2764
end exclusive: true
exact text: 1.4 Ankylosing Spondylitis Adalimumab-fkjp is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2623

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 18 · positive indication candidate

application numbers

BLA761154

brand names

Adalimumab

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3139
end exclusive: true
exact text: be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-fkjp is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease Adalimumab-fkjp is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-fkjp is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab product
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2565

current approval status

not_reconciled

duplicate text group

dup-13fe4a878bc4bc90b11d

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-594e4f9bafe86f157ea8

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

end: 2813
end exclusive: true
exact text: is indicated
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2801

qualifier mentions

context exact
eatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
2890
end exclusive
true
exact text
adults
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
2884
context exact
moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
2913
end exclusive
true
exact text
pediatric patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
2895
context exact
ely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
2928
end exclusive
true
exact text
6 years of age
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
2914

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 2939
end exclusive: true
exact text: 1.5 Crohn’s Disease Adalimumab-fkjp is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2765

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 19 · positive indication candidate

application numbers

BLA761154

brand names

Adalimumab

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3280
end exclusive: true
exact text: ankylosing spondylitis. 1.5 Crohn’s Disease Adalimumab-fkjp is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-fkjp is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7 ) ] . 1.7 Pla
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2740

current approval status

not_reconciled

duplicate text group

dup-66e27503cbb7d1928a51

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-105efb8ca7544d241acf

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

end: 2991
end exclusive: true
exact text: is indicated
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2979

qualifier mentions

context exact
ment of moderately to severely active ulcerative colitis in adult patients.
kind
age
polarity
not_inferred
span
end
3079
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
3065

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 3080
end exclusive: true
exact text: 1.6 Ulcerative Colitis Adalimumab-fkjp is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2940

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 20 · limitation of use

application numbers

BLA761154

brand names

Adalimumab

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 3472
end exclusive: true
exact text: in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-fkjp is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7 ) ] . 1.7 Plaque Psoriasis Adalimumab-fkjp is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and whe
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 2881

current approval status

not_reconciled

duplicate text group

dup-408e71fe3cc6d2122411

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-79be840ef97ff1bc017a

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 3272
end exclusive: true
exact text: Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7 ) ] .
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 3081

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 21 · positive indication candidate

application numbers

BLA761154

brand names

Adalimumab

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3730
end exclusive: true
exact text: tients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7 ) ] . 1.7 Plaque Psoriasis Adalimumab-fkjp is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-fkjp should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppura
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 3073

current approval status

not_reconciled

duplicate text group

dup-f2612e7e604f3957110b

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-5e72fc9d34f07d10078e

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

end: 3322
end exclusive: true
exact text: is indicated
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 3310

qualifier mentions

context exact
Psoriasis Adalimumab-fkjp is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
kind
age
polarity
not_inferred
span
end
3358
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
3344

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 3530
end exclusive: true
exact text: 1.7 Plaque Psoriasis Adalimumab-fkjp is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 3273

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 22 · risk or warning

application numbers

BLA761154

brand names

Adalimumab

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 3905
end exclusive: true
exact text: treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-fkjp should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa Adalimumab-fkjp is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis Adalimumab-fkjp is indicated for the treatmen
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 3331

current approval status

not_reconciled

duplicate text group

dup-0de064b436d44923dfc7

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-0724b64aa1734761271e

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 3705
end exclusive: true
exact text: Adalimumab-fkjp should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] .
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 3531

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 23 · positive indication candidate

application numbers

BLA761154

brand names

Adalimumab

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3983
end exclusive: true
exact text: ically less appropriate. Adalimumab-fkjp should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa Adalimumab-fkjp is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis Adalimumab-fkjp is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 3506

current approval status

not_reconciled

duplicate text group

dup-e88dad1ac4ccbaf64002

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-0b18236028e8375fed4a

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

end: 3763
end exclusive: true
exact text: is indicated
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 3751

qualifier mentions

context exact
treatment of moderate to severe hidradenitis suppurativa in adult patients.
kind
age
polarity
not_inferred
span
end
3846
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
3832

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 3847
end exclusive: true
exact text: 1.8 Hidradenitis Suppurativa Adalimumab-fkjp is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 3706

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 24 · positive indication candidate

application numbers

BLA761154

brand names

Adalimumab

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3983
end exclusive: true
exact text: ts with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa Adalimumab-fkjp is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis Adalimumab-fkjp is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 3648

current approval status

not_reconciled

duplicate text group

dup-001f59bfae1a31bdc329

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-FKJP

ind-span-98953d53b319ad680482

label id

39c67c8f-7fbd-a17a-1535-5d41ece68818

positive predicate support span

end: 3888
end exclusive: true
exact text: is indicated
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 3876

qualifier mentions

context exact
f non-infectious intermediate, posterior, and panuveitis in adult patients.
kind
age
polarity
not_inferred
span
end
3982
end exclusive
true
exact text
adult patients
label id
39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start
3968

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 3983
end exclusive: true
exact text: 1.9 Uveitis Adalimumab-fkjp is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.
label id: 39c67c8f-7fbd-a17a-1535-5d41ece68818
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 667f649c01946a0dcffb55a3cc8ed8b01b76d03d2cb88bed4bfdc81ec3473d95
start: 3848

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239c67c8f-7fbd-a17a-1535-5d41ece68818%22

spl effective date

2026-01-12

spl set id

5cde907d-6747-0e62-db25-1718ee717fe7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Preserved source evidence · Not medical advice